A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13? in Healthy Infants

Project: Other project

StatusActive
Effective start/end date2/8/172/7/20

Funding

  • Merck Sharp & Dohme Corporation: $124,801.01